Feibi recipe no. 2 attenuates bleomycin-induced pulmonary fibrosis in mice: involvement of N-methyl-D-aspartate receptor-related iron dyshomeostasis and ferroptosis
Background Pulmonary fibrosis (PF) is a progressive disease with limited therapeutic options, in which iron dyshomeostasis and ferroptosis have been increasingly implicated. This study investigated the anti-fibrotic effects of Feibi Recipe No. 2 (FBR2), a traditional Chinese medicine formula, and explored potential links among N-methyl-D-aspartate receptor (NMDAR) signaling, iron regulatory protein/iron-responsive element (IRP/IRE)-associated iron regulation, and ferroptosis-related changes. Methods The phytochemical profile of FBR2 was characterized by UHPLC-MS/MS. A bleomycin (BLM)-induced PF mouse model was established, with lung tissues collected on days 7, 14, and 21. Mice received FBR2 at 10.51, 21.02, or 42.04 g kg -1 ·day -1 (botanical-drug equivalents), with deferoxamine (DFO) as a comparator; the 21.02 g kg -1 ·day -1 dose was selected for subsequent time-course and mechanistic analyses. NMDAR signaling was modulated using the antagonist memantine (ME) and the agonist NMDA. Proteomic changes were profiled by data-independent acquisition (DIA), with selected proteins assessed by parallel reaction monitoring (PRM). Fibrotic phenotypes, iron-related changes, and ferroptosis-related alterations were evaluated by histological, immunological, biochemical, flow-cytometric, and IRP/IRE-related protein analyses. Results FBR2 attenuated BLM-induced PF in a stage-associated manner, preserving early-stage surfactant protein C (SPC)-positive alveolar epithelial cells, attenuating the early interleukin-6 (IL-6) inflammatory response, inhibiting mid-to-late-stage α-smooth muscle actin (α-SMA) expression, and decreasing late-stage collagen deposition. At day 21, FBR2-M significantly reduced Masson’s trichrome-positive area, modified Ashcroft score, and collagen I (Col I)-positive area (all vs. BLM, P < 0.0001). Proteomics identified 256 FBR2-reversed proteins enriched in iron metabolism- and ferroptosis-related pathways. Further analyses showed that FBR2 reduced pulmonary Fe 2+ accumulation and ameliorated iron-regulatory abnormalities, antioxidant impairment, lipid peroxidation, and mitochondrial dysfunction, collectively consistent with attenuation of ferroptosis-related injury. Pharmacological modulation of NMDAR revealed distinct response patterns: ME produced effects broadly similar to those of FBR2, whereas the FBR2 + NMDA group exhibited greater iron accumulation, more pronounced ferroptosis-related alterations, and more severe fibrotic changes than the FBR2 group, consistent with the potential involvement of NMDAR-related signaling in FBR2-mediated protection. Conclusion FBR2 attenuated PF progression, with its protective effects associated with NMDAR-related signaling, IRP/IRE-associated iron regulation, and attenuation of ferroptosis-related injury. Together, these findings support the involvement of these interconnected processes in FBR2-mediated protection against PF.
Authors
- Yang Jiao (ORCID: https://orcid.org/0000-0003-0262-4901)
- Fang Cao (ORCID: https://orcid.org/0000-0003-0534-9781)
- Wan Wei (ORCID: https://orcid.org/0009-0006-5807-3263)
- Yaodong Cai
- Jie Niu
- Zhisong Wu
- Tonghua Liu
- Yang Li
Institutions
- Beijing University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fphar.2026.1927029
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China